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Abstract 
Type I Dehydroquinase (DHQ1) is a class I aldolase enzyme that catalyzes the reversible 
dehydration of 3-dehydroquinic acid to form 3-dehydroshikimic acid by multi-step mechanism that 
involves the formation of Schiff base species’. DHQ1 is present in plants and several bacterial 
sources but it does not have any counterpart in human cells. It has been suggested that DHQ1 may 
act as a virulence factor in vivo and therefore a promising target in the search for new anti-virulence 
agents to combat widespread antibiotic resistance. This review covers recent progress in the 
structure-based design and chemical modifications caused by selective irreversible inhibitors. 
Computational studies aimed at understanding the experimentally obtained covalent modifications 
and inhibitory potencies of these inhibitors are also described. 
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The challenge of antibiotic resistance – an overview of the problem 
The discovery and subsequent development of penicillin was one of the major achievements in 
medicine in the 20th century and this marked the beginning of the ‘golden age’ of antibiotic therapy. 
After the discovery of penicillin, a wide therapeutic arsenal was developed to combat various 
infectious diseases that had previously been potentially fatal. Unfortunately, the optimism associated 
with this success also led to the misconception that antibiotics were ‘miraculous drugs’ with ‘power’ 
that largely exceeded their real pharmacological properties. In most European countries, antibiotics 
are the second most widely used class of drugs after simple analgesics. The excessive use of these 
drugs, and in many cases their inappropriate use, in medicine, veterinary medicine and agriculture 
has led to a rapid and ever-increasing emergence of strains that are resistant to antibiotics. Today, 
infectious diseases caused by the development of drug resistance have become one of the most 
important public health issues of the early 21st century [1−5]. Severe hospital- and community-
acquired bacterial infections are rising sharply, with antibiotic-resistant nosocomial infections being 
a major concern [6,7]. Antibacterial drug resistance also has a huge economic and social impact 
[8,9]. For example, the European Centre for Disease Prevention and Control (ECDC) estimates that 
each year antimicrobial resistance results in 25,000 deaths and related costs of over 1.5 billion € in 
healthcare expenses and productivity losses. Despite the recognized need for new antibiotics, the 
investment in antibiotic research and development by the major pharmaceutical companies has 
declined dramatically in the last 40 years [10]. Therefore, if we do not want to return to the pre-
antibiotic era, it is necessary to develop alternative therapies, in particular drugs with new 
mechanisms of action, and to identify unexplored bacterial targets and gain a detailed knowledge of 
the catalytic mechanism and/or the binding determinants of those targets to combat the growth of 
antibiotic-resistant bacteria [11−13]. 
Anti-virulence therapies – an alternative 
The most widely used strategy to combat bacterial infections is based on the disruption of their 
viability by preventing the synthesis and assembly of key components for bacterial survival [14]. 
Almost all clinically used antibiotics inhibit cell wall biosynthesis, DNA replication, RNA 
transcription, folate biosynthesis, or protein biosynthesis by blocking fewer than twenty-five targets 
[1].
 
Although this strategy is highly effective, it causes substantial stress to the bacterium and this 
favors the growing emergence of antibiotic-resistant strains [15]. Therefore, in addition to the 
discovery of novel compounds to target bacterial viability, in recent years a great deal of effort has 
been devoted to the development of alternative therapies that target bacterial virulence, i.e., the 
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ability of a pathogen to cause disease [14−22]. The attenuation of bacterial virulence makes the 
bacterium less able to establish successful infection and, in consequence, it is cleared by the host 
immune response [14, 15]. Therefore, anti-virulence drugs will disarm bacteria and will create an in 
vivo scenario similar to that achieved by vaccination with a live attenuated strain. Such a strategy 
might lessen the pressure for the development of resistance as most virulence traits are not essential 
for bacterial survival. In principle, these types of drugs will also preserve the gut microbiota.  
Type I dehydroquinase – an anti-virulence target 
Among the enzymes that may be promising targets in the search for new anti-virulence agents to 
combat resistant bacteria it is important to highlight type I Dehydroquinase (DHQ1). It has been 
suggested that this enzyme may act as a virulence factor in vivo as the deletion of the aroD gene, 
which encodes DHQ1 from Salmonella typhi and Shigella flexneri, has been proven to afford 
satisfactory live oral vaccines, with the latter providing monkeys with protection against oral 
challenge with live S. flexneri 2457T [23−28]. The important features of the DHQ1 enzyme have not 
gone unnoticed by the scientific community and a great deal of effort has been focused on the 
development of inhibitors of this enzyme. The structure-based design of inhibitors of this challenging 
enzyme has undoubtedly benefited significantly from extensive mechanistic and biochemical studies 
[29], the increasing availability of DHQ1 crystal structures from different bacterial sources, as well 
as from the recent advances in computational methods that have consolidated their value as 
important complementary tools that can assist in providing a detailed knowledge of the enzymatic 
mechanism, the enzyme binding requirements and the essential motions required for catalysis. This 
review will provide an overview of the recent achievements related to the irreversible inhibition 
(covalent modification) of the DHQ1 enzyme. A detailed view of the substrate binding requirements 
and the essential motion for catalysis is also described. Particular attention will be focused on 
explaining the chemical modifications caused by these inhibitors. 
Dehydroquinase (3-dehydroquinate dehydratase, DHQ, EC 4.2.1.10) is the third enzyme in the 
shikimic acid pathway. This route involves seven enzymes that catalyze the sequential conversion of 
erythrose-4-phosphate and phosphoenolpyruvate to chorismic acid (Figure 1) [29]. The enzymes 
involved in the shikimic acid pathway are present in bacteria, fungi and higher plants, but they are 
absent in mammals. Some of these enzymes have also been detected in Toxoplasma gondii (which 
causes malaria) and Plasmodium falciparum extracts [30−32].  
DHQ catalyzes the reversible dehydration of 3-dehydroquinic acid (1) to form 3-dehydroshikimic 
acid (2) [29,33]. This reaction is part of two metabolic pathways: the biosynthetic shikimic acid 
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pathway, which leads to chorismic acid, and the catabolic quinic acid pathway, in which quinic acid 
is converted into protocatechuate (Figure 1). Chorismic acid is the precursor in the synthesis of 
aromatic amino acids, L-Phe, L-Tyr and L-Thr, and other important aromatic compounds such as 
folate cofactors, ubiquinone and vitamins E and K. Whereas protocatechuate is converted via the β-
adipate pathway to acetyl-CoA and succinyl Co-A. There are two distinct types of DHQ enzymes, 
known as type I (DHQ1, aroD gene) and type II (DHQ2, aroD/aroQ gene), which have different 
biochemical and biophysical properties and they do not show sequence similarity (Table 1) [34]. 
DHQ1, which is found in plants, fungi and many bacterial species such as Salmonella typhi, 
Staphylococcus aureus, Escherichia coli, Salmonella enterica subsp. enterica serovar typhimurium 
and Clostridium difficile, is exclusively biosynthetic and is a heat-labile dimer with a subunit of 
around 27 KDa (Figure 2A) [35,36]. In contrast, DHQ2 has both biosynthetic and catabolic roles. It 
is a heat-stable dodecamer formed from a tetramer of trimers, where a trimer is the minimum 
catalytic unit of the enzyme [37] (Figure 2B), and it has a subunit of 1618 KDa. DHQ2 is essential 
in pathogenic bacteria such as Mycobacterium tuberculosis (aroD gene), which is responsible for 
tuberculosis, and Helicobacter pylori (aroD/aroQ gene), which is the causative agent of gastric and 
duodenal ulcers and has also been classified as a type I carcinogen [38]. DHQ2 is a particularly 
attractive target for the development of new anti-tubercular drugs and alternative therapies for the 
treatment of Helicobacter pylori infections [39–42]. In this respect, compounds that target the DHQ2 
enzyme would have an influence on bacterial viability. The fact that two DHQ enzymes have 
evolved to catalyze the same reaction by entirely different mechanisms and stereochemical courses 
has been used in the design of compounds that specifically inhibit either the type I or type II enzymes 
[34]. This review is focused on the DHQ1 enzyme.   
DHQ1 mechanism – nucleophilic catalysis  
DHQ1 is a class I aldolase enzyme that catalyzes the overall syn elimination of water from 3-
dehydroquinic acid (1) by a multi-step mechanism that involves the formation of a Schiff base 
species. In the formation of such covalent intermediates Nature has found an excellent way to 
address mechanistically challenging transformations around the carbonyl group in aqueous solution 
[43−46]. Good examples are the PLP-dependent enzymes, which catalyze a wide range of reactions 
[47,48]. For enzyme-catalyzed reactions, covalent catalysis is a particularly effective strategy 
because: (a) it can place its substrate in the correct arrangement for further enantio- or 
diastereoselective transformations; (b) the formation of covalent intermediates in the reaction 
mechanism helps to stabilize subsequent transition states by lowering the activation energy; (c) it can 
generate a very high effective concentration of a desolvated nucleophile or base with the consequent 
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huge rate acceleration. Thus, considering that enzyme active sites are largely shielded from the 
solvent environment, usually by a substrate-covering loop that closes over the active site after 
substrate binding, the reactive side chain residues are likely to be desolvated and therefore a high 
effective concentration of a nucleophile or a base is achieved. 
The reaction catalyzed by DHQ1 is initiated by the formation of a Schiff base between the C3 
carbonyl group of the substrate and an essential lysine (Lys170 in S. typhi) (Figure 3). The role of the 
Schiff base is to act as an electron sink and it may also play a role in distorting the cyclohexyl ring to 
make the equatorial C2 hydrogen more reactive [49,50]. A basic residue of the active site then 
removes the C2 equatorial hydrogen (pro-R) to afford an enamine, which undergoes acid-catalyzed 
elimination of the C1 hydroxyl group  a reaction that is mediated by an essential histidine (His143 
in S. typhi) acting as a proton donor [51]. The role in the enzymatic mechanism of this histidine has 
been the subject of much controversy. Site-directed mutagenesis and biochemical studies have 
shown that His143 is clearly involved in both the formation and subsequent hydrolysis of the Schiff 
base intermediates [52−56]. In addition, based on the proximity of His143 to the C2 carbon in the 
crystal of the substrate-Schiff base (PDB entry 3M7W, 1.95 Å), it was also suggested that this 
residue would also be the base that removes the C2 equatorial hydrogen [57] (Figure 4A). However, 
its role as a general base appears to be more complex because the replacement of His143 residue by 
and an alanine (variant H143A protein), which showed a 10
6
-fold reduction in catalytic activity, is 
able to slowly transform substrate to product but stalls the hydrolytic release of product from the 
active site [55]. Computational studies suggest that the product-Schiff base hydrolysis is the rate-
determining step [58−60]. The crystal structure of the reduced form of the product-Schiff base (PDB 
entry 1SFJ, 2.4 Å, [61]), which was obtained by reduction of the imine bond with sodium 
borohydride, has also been solved (Figure 4B) [62]. This covalent attachment of the product 
molecule to the DHQ1 from E. coli does not cause a significant change in the protein conformation 
but it causes a dramatic increase in the stability of the protein against proteolysis [63,64]. Thus, the 
melting temperature of the covalently modified protein is 40 ºC higher than that of the unmodified 
one.  
DHQ1 active site and substrate binding  
Analysis of the amino acid sequence in various DHQ1 enzymes reveals that the active site is 
highly conserved (Figure 5). The available crystal structures of the Schiff base intermediates and 
Molecular Dynamics (MD) simulation studies carried out with the Michaelis complex of DHQ1 from 
Salmonella typhi (St-DHQ1) showed that the substrate binds in the active site by a series of strong 
electrostatic and hydrogen-bonding interactions [65]. This Michaelis complex was created from the 
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crystal structure of St-DHQ1 in complex with (2R)-2-methyl-3-dehydroquinic acid (PDB entry 
4CNO, 1.5 Å, [65]), which is a substrate analog that does not form an imine linkage with the enzyme 
and leads to an open conformation of the substrate-covering loop. In particular, the substrate is 
anchored to the active site by a salt-bridge between its carboxylate group and the guanidinium group 
of Arg213, which has previously been identified by chemical modification as the key residue for 
carboxylate recognition [50,66], along with a bidentate hydrogen bond between the carboxylate 
group of the conserved Glu46 and the C4 and C5 hydroxyl groups of the substrate (Figure 4). The C4 
hydroxyl group of the inhibitor also interacts by hydrogen bonding with the guanidinium group of 
Arg82 and a water molecule that is found in several crystal structures forming a bridge between 
Asp114 and Glu46, probably to avoid repulsion between the two residues. The C5 hydroxyl group 
establishes two additional hydrogen bonds, one with the guanidinium group of the conserved Arg48 
and one with the loop that closes the active site. The latter interaction, along with the hydrogen bond 
between the carboxylate group of the substrate and the side chain of a conserved Gln236, contributes 
to close the active site tightly. Harris et al. [67] showed that the binding interactions involving the C4 
hydroxyl group are very important for imine formation. Thus, whereas the removal of the C5 
hydroxyl group in 1 cause a reduction in specificity by 10
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), removal of both C4 and C5 hydroxyl groups does not lead to formation of the Schiff 
base. Moreover, the C1 hydroxyl group of the ligand and the guanidinium group of Arg82 interact 
through a bridging water molecule. Finally, the appropriate disposition of the cyclohexane ring is 
controlled by key CH-π interactions between the phenyl ring of the functionally conserved Phe225 
(in S. typhi) and the axial hydrogens of the cyclohexane ring of the inhibitor. This residue, which is 
embedded within an apolar pocket involving Ile201, Val139, Leu78 and Ala223, seems to act as a 
‘bottom lid’ of the active site to isolate this part of the active site from the solvent environment and it 
also blocks one of the faces of the substrate for catalysis. Comparison of the amino acid sequence in 
several DHQ1 enzymes (Figure 5) revealed that in some cases this phenylalanine is replaced by a 
tyrosine, as for DHQ1 from S. aureus (Sa-DHQ1). In those cases, such interactions are only 
observed with the axial C2 hydrogen because the tyrosine phenol ring is shifted towards the essential 
lysine binding pocket. In both cases, the axial C2 hydrogen is protected by these aromatic residues. 
MD simulation studies carried out on the Michaelis complex of St-DHQ1 suggest that the 
formation of this complex involves five key steps [65] (Figure 6): (1) folding of the substrate-
covering loop triggered by the conserved Gln236; (2) reduction of the loop flexibility by a series of 
attractive hydrogen-bonding interactions involving Pro234, Ala233, Ser232 and Gln236 [66] 
residues that are located in the loop; (3) pushing the substrate into the bottom of the active site, 
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which involves Arg213 and Glu46 residues and the loop; (4) sealing of the active site with the 
entrance of the conserved Phe145 side chain into the active site after a small folding of the loop 
containing residues 144–151, a process that is triggered by a hydrogen-bonding interaction with the 
neighboring loop that contains residues 174–178; and (5) capture of the Phe145 side chain inside the 
active site by the conserved Met205 residue. These studies also showed that a closed conformation of 
the substrate-covering loop that seals the active site from the solvent environment is required for 
catalysis. 
Covalent DHQ1 inhibitors 
The first irreversible inhibitors of the DHQ1 enzyme, compounds 3−5, were reported by Bugg et 
al. [68] (Figure 7). These substrate analogs with reactive functional groups, which were synthesized 
as racemic mixtures, proved to inhibit irreversibly DHQ1 from E. coli with Ki values between 0.4 
and 1.1 mM, with epoxide 3 being the most potent of the three. However, details of the inhibition 
mechanism were not reported.  
Later on, reasoning that the reaction catalyzed by DHQ1 involves the abstraction of the equatorial 
(pro-R) C2 hydrogen of 3-dehydroquinic acid (1), this hydrogen was replaced by a halogen, i.e., 
(2R)-2-fluoro- (6a) and (2R)-2-bromo-3-dehydroquinic acid (6b), as a strategy to inhibit the enzyme 
[69,70] (Figure 7). These compounds, which are substrates for the DHQ2 enzyme since they still 
contain the axial C2 hydrogen that is removed by the enzyme [71], proved to be time-dependent 
irreversible inhibitors of DHQ1 from E. coli with Ki values of 80 µM and 3.7 mM, respectively. The 
electrospray mass spectra of the partially inactivated enzyme with compounds 6 showed the presence 
of covalently modified proteins corresponding to an additional mass of 123, which were similar in 
both cases. It was suggested that this chemical modification is due to the formation of compound 10, 
which would be obtained by a decarboxylation reaction (Figure 8). The distortion of the cyclohexyl 
ring induced by the formation of the Schiff base probably favors an antiperiplanar disposition of the 
carboxylate and the halide groups and this would allow the decarboxylation process to occur. 
Recently, epoxides 7 and 8 were designed as irreversible inhibitors of the DHQ1 enzyme to 
study the binding requirements of the linkage to the enzyme [72]. Both epoxides proved to have 
a highly differentiated activity against St-DHQ1. The epoxide with the R configuration, compound 
8, proved to be a weak inhibitor with an IC50 of 1 mM and this did not cause covalent modification 
of the enzyme. In contrast, the epoxide with the S configuration, compound 7, was found to be a 
time-dependent irreversible inhibitor of St-DHQ1. A 274 µM concentration of epoxide 7 caused 
50% enzyme inactivation in 30 minutes and 75% enzyme inactivation in 2 hours. These 
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studies also allowed the description of the first crystal structure of St-DHQ1 covalently 
modified by an inhibitor (PDB entry 4CLM) (Figures 9A and 9B). This structure, which was 
obtained by co-crystallization and was determined at 1.4 Å, revealed that surprisingly the 
modified ligand is covalently attached to the essential Lys170 through the formation of a 
stable Schiff base, which has two possible arrangements. The expected hydroxyl amino 
derivative that would be obtained after nucleophilic ring opening of the epoxide group in 7 by 
Lys170 was not obtained as electron density was not observed for the corresponding C3 hydroxyl 
group (Figure 9A). MD simulation studies carried out with the St-DHQ1/7 binary complex suggest 
that the resulting St-DHQ1/7 adduct would be obtained by activation of the epoxide oxygen by the 
essential histidine followed by nucleophilic ring opening of the epoxide by the lysine from the 
opposite face and subsequent dehydration and isomerization reactions. These studies provide strong 
evidence that the enzyme appears to be designed to form the substrate-Schiff base by activation and 
correct positioning of the oxygen atom of the ketone group in the natural substrate by His143 and 
subsequent nucleophilic attack by Lys170 from the Si face of the ketone group. This process requires 
an active site that is shielded from the solvent environment by the substrate-covering loop. 
The proposed covalent modification mechanism is shown in Figure 10. Firstly, nucleophilic attack 
by the -amino group of the essential lysine to epoxide 7 by activation of the essential histidine 
would take place to afford adduct 10. The resulting adduct could then be deprotonated by the neutral 
His143 to give the corresponding amino alcohol II. For the St-DHQ1 enzyme, a conserved water 
molecule (W173 in PDB entry 4CLM), which is also observed in all the available DHQ1 crystal 
structures, remains fixed between the side chain of the conserved Asp114 and Glu46 residues. In this 
arrangement, Asp114 would act as the base that deprotonates this water molecule to afford a 
hydroxide group, which triggers the elimination reaction. This hydroxide anion would be stabilized 
by the guanidinium group of Arg82. Dehydration of the C3 hydroxyl group would be mediated by 
His143 acting as a proton donor. As a result, enamine II, which is in equilibrium with its Schiff base 
11, would be obtained. The crystal structure of the latter adduct was obtained by co-crystallization of 
St-DHQ1 with epoxide 7 after several weeks (PDB entry 4CLM).  
Non-covalent DHQ1 Inhibitors 
 Ratia et al. carried out a high-throughput screening study and identified three non-covalent 
inhibitors of DHQ1 from Clostridium difficile, compounds 12−14, which had IC50 values between 31 
and 35 µM (Figure 11) [73,74]. NMR experiments showed that these compounds compete with the 
reaction product binding site. Considering that (a) these compounds proved to be selective inhibitors 
of the C. difficile enzyme but they were inactive against other DHQ1 enzymes such as the S. enterica 
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enzyme and (b) that the DHQ1 active site is highly conserved, the authors suggested that these 
compounds bind to the DHQ1 from C. difficile with the substrate-binding loop in the open 
conformation. The binding mode of these inhibitors is still unknown. 
Future Perspective 
After a gap in innovation of around 40 years (1960−2000) in the search for new antibiotic classes, 
and considering that very few new antibiotics have been brought to the market in the last decade, 
future research into the discovery of novel drugs and therapies promises to be exciting and 
challenging. Although the complexity of bacteria, which have had billions of years of evolution to 
cope with harsh environments, makes bacterial resistance an inevitable phenomenon, the 
development of drugs that deal with unexplored targets and/or with new mechanisms of action will 
help to reduce the rate and spread of this resistance. In this sense, anti-virulence drugs, which block 
the ability of bacteria to cause a disease or disrupt the interaction between the host and the pathogen, 
are attractive options. The significant effort devoted over the past few decades to understand how 
bacteria cause disease, along with the increasing availability of bacterial genome sequences, has 
created new opportunities for drug discovery that are increasingly being explored. More work needs 
to be done on the identification of unknown virulence factors involved in relevant pathogenic 
bacteria and a detailed knowledge of their mechanism of action needs to be gained. This knowledge 
will be an excellent starting point for the rational design of compounds and will provide a wider 
repertoire of agents to combat bacterial virulence.  
Although only a few inhibitors of the type I dehydroquinase enzyme − a promising virulence factor 
in vivo − have been developed to date, prelimary in vitro anti-virulence studies show their ability to 
reduce bacterial virulence and this encourages further studies on this target. A wider variety of 
covalent and non-covalent inhibitors based on the scaffolds that have already been described is 
needed to improve on the anti-virulence activity achieved to date. Covalent inhibitors are particularly 
attractive due to their higher efficiency, their low sensitivity toward pharmacokinetic parameters and 
their longer duration of action [75,76]. However, care must be taken when selecting functional 
groups for specific covalent linkage to the enzyme to avoid the production of non-specific drugs. As 
for the other enzymes involved in the shikimic acid pathway, the binding requirements of this 
enzyme, in particular regarding the carboxylate recognition that is required for good binding affinity, 
and the high polarity of the residues involved in the substrate recognition represent the most 
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Executive summary 
The challenge of antibiotic resistance – an overview of the problem 
 Drugs with new mechanisms of action, the identification of unexplored bacterial targets as 
well as a detailed knowledge of the catalytic mechanism and/or the binding determinants of 
those targets to combat the growth of antibiotic-resistant bacteria is urgently needed. 
Anti-virulence therapies – an alternative 
 Anti-virulence drugs will disarm bacteria and will create an in vivo scenario similar to that 
achieved by vaccination with a live attenuated strain. 
Type I dehydroquinase – an anti-virulence target 
 Type I dehydroquinase is a promissing target in the search of new anti-virulence agents to 
combat the widespread resistance to antibiotics.  
 There are two distinct types of DHQ enzymes (DHQ1 and DHQ2) and these have different 
biochemical and biophysical properties. 
 DHQ1 and DHQ2 enzymes catalyze the same reaction by very different mechanisms. 
DHQ1 mechanism – covalent catalysis 
 It is a class I aldolase involving the formation of Schiff-base species 
 Syn elimination of water.  
DHQ1 active site and substrate binding  
 Details of the binding requeriments and essential motion for catalysis is described. 
Covalent DHQ1 inhibitors 
 First irreversible inhibitors, compounds 3−5. 
 (2R)-2-halo-3-dehydroquinic acids (6). 
 Epoxides 7 and 8. 
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Non-covalent DHQ1 inhibitors 




Virulence: It is the magnitude of the morbidity and the increase in the likelihood of mortality 
resulting from the colonization and proliferation of bacteria in or on a host. 
Nucleophilic catalysis: This type of enzymatic catalysis is a subtype of covalent catalysis and it 
involves nucleophilic attack of an active site residue to a reactive functional group of the substrate 
and subsequent formation of a covalent intermediate with the enzyme. 
Molecular dynamics (MD) simulations: These computational studies provide information about 
the dynamic behavior of complex molecular systems such as receptors and enzymes that can be 
studied in the presence or absence of ligands in aqueous solution. In comparison with docking 
studies, in which the macromolecule is considered as a rigid system and the ligand is flexible, 
MD simulation studies consider both the receptor and the ligand to be flexible.  
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Figure 1. The shikimic acid pathway. The reaction catalyzed by the dehydroquinase enzyme is part 
of two metabolic pathways: the biosynthetic shikimic acid pathway leading to chorismic acid and the 
catabolic quinic acid pathway that converts quinic acid into protocatechuate. 
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Table 1. Comparison of the different characteristics and mechanism of the DHQ enzymes 




Subunit 27 KDa 
Heat-stable dodecamer (tetramer of 
trimers) 

















syn elimination of water 
equatorial (pro-R) C2 hydrogen  
covalent linkage to the enzyme (Lys) 
Schiff base species 
anti elimination of water 
axial (pro-S) C2 hydrogen  









Figure 2. Tridimensional structure of the DHQ enzymes. A) DHQ1. B) DHQ2. Note how DHQ1 
is a dimer whereas DHQ2 is a tetramer of trimers. Only the trimer is shown. Note how the DHQ2 
active site is located in the interface between two chains. The substrate-covering loop for both 











Figure 4. Crystal structures of DHQ1 substrate- and product-Schiff bases. A) Substrate-Schiff 
base of DHQ1 from S. typhimurium LT2 (PDB entry 3M7W, 1.95 Å, [51]). B) Product-Schiff base of 
DHQ1 from S. aureus (PDB entry 1SFJ, 2.4 Å, [48]). Hydrogen bonding and electrostatic 
interactions are shown as red dashed lines. Relevant residues are shown and labeled. 
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DHQ1_AA         MLIA----------------VPLDDTNFSENL---KKAKEKGADIVELRV 
DHQ1_CD         MKRKVQVKNITIGEGRPKICVPIIGKNKKDIIKEAKELKDACLDIIEWRV 
DHQ1_EC         MKT-VTVKDLVIGTGAPKIIVSLMAKDIASVKSEALAYREADFDILEWRV 
DHQ1_SA         MTH-VEV----VATITPQL-------YIEETLIQKINHRIDAIDVLELRI 
DHQ1_SA2        MTH-VEV----VATIAPQL-------SIEETLIQKINHRIDAIDVLELRI 
DHQ1_ST         MKT-VTVKNLIIGEGMPKIIVSLMGRDINSVKAEALAYREATFDILEWRV 
DHQ1_ST2        MKT-VTVRDLVVGEGAPKIIVSLMGKTITDVKSEALAYREADFDILEWRV 
                *                                     :    *::* *: 
 
DHQ1_AA         DQFSDTS-LNYVKEKLEEV--HSQGLKTILTIRSPEEGGREVKNREELFE 
DHQ1_CD         DFFENVENIKEVKEVLYELRSYIHDIPLLFTFRSVVEGGEKLISRDYYTT 
DHQ1_EC         DHYADLSNVESVMAAAKILRETMPEKPLLFTFRSAKEGGEQAISTEAYIA 
DHQ1_SA         DQFENVT-VDQVAEMITKLKVMQDSFKLLVTYRTKLQGGYGQFTNDSYLN 
DHQ1_SA2        DQIENVT-VDQVAEMITKLKVMQDSFKLLVTYRTKLQGGYGQFINDLYLN 
DHQ1_ST         DHFMDIASTQSVLTAARVIRDAMPDIPLLFTFRSAKEGGEQTITTQHYLT 
DHQ1_ST2        DHFANVTTAESVLEAAGAIREIITDKPLLFTFRSAKEGGEQALTTGQYID 
                *   :    . *      :         :.* *:  :**            
 
DHQ1_AA         EL-----SPLSDYTDIELSSRGLLVK--L-YNITKEAGKKLIISYHNFEL 
DHQ1_CD         LNKEISNTGLVDLIDVELFMGDEVID--EVVNFAHKKEVKVIISNHDFNK 
DHQ1_EC         LNRAAIDSGLVDMIDLELFTGDDQVK--ETVAYAHAHDVKVVMSNHDFHK 
DHQ1_SA         LISDLANINGIDMIDIEWQADIDIEKHQRIITHLQQYNKEVIISHHNFES 
DHQ1_SA2        LISDLANINGIDMIDIEWQADIDIEKHQRIITHLQQYNKEVVISHHNFES 
DHQ1_ST         LNRAAIDSGLVDMIDLELFTGDADVK--ATVDYAHAHNVYVVMSNHDFHQ 
DHQ1_ST2        LNRAAVDSGLVDMIDLELFTGDDEVK--ATVGYAHQHNVAVIMSNHDFHK 
                           *  *:*        .        :     :::* *:*.  
 
DHQ1_AA         TPPNWIIREVLREGYRYG-GIPKIAVKANSYEDVARLLCISRQ-----VE 
DHQ1_CD         TPKKEEIVSRLCRMQELGADLPKIAVMPQNEKDVLVLLEATNEMFKIYAD 
DHQ1_EC         TPEAEEIIARLRKMQSFDADIPKIALMPQSTSDVLTLLAATLEMQEQYAD 
DHQ1_SA         TPPLDELQFIFFKMQKFNPEYVKLAVMPHNKNDVLNLLQAMSTFS-DTMD 
DHQ1_SA2        TPPLDELQFIFFKMQKFNPEYVKLAVMPHNKNDVLNLLQAMSTFS-DTMD 
DHQ1_ST         TPSAEEMVLRLRKMQALGADIPKIAVMPQSKHDVLTLLTATLEMQQHYAD 
DHQ1_ST2        TPAAEEIVQRLRKMQELGADIPKIAVMPQTKADVLTLLTATVEMQERYAD 
                **    :   : .    .    *:*: .:.  **  **           : 
 
DHQ1_AA         GEKILISMGDYGKISRLAGYVFGSVITYCSLEKAFAPGQIPLEEMVELRK 
DHQ1_CD         RPIITMSMSGMGVISRLCGEIFGSALTFGAAKSVSAPGQISFKELNSVLN 
DHQ1_EC         RPIITMSMAKTGVISRLAGEVFGSAATFGAVKKASAPGQISVNDLRTVLT 
DHQ1_SA         CKVVGISMSKLGLISRTAQGVFGGALTYGCIGEPQAPGQIDVTDLKAQVT 
DHQ1_SA2        CKVVGISMSKLGLISRTAQGVFGGALTYGCIGEPQAPGQIDVTDLKAQVT 
DHQ1_ST         RPVITMSMAKEGVISRLAGEVFGSAATFGAVKQASAPGQIAVNDLRSVLM 
DHQ1_ST2        RPIITMSMSKTGVISRLAGEVFGSAATFGAVKKASAPGQISVADLRTVLT 
                   : :**.  * *** .  :**.. *: .  .  ***** . ::      
 
DHQ1_AA         KFYR--L 
DHQ1_CD         LLHKSIN 
DHQ1_EC         ILHQ--A 
DHQ1_SA         L-----Y 
DHQ1_SA2        L-----Y 
DHQ1_ST         ILHN--A 
DHQ1_ST2        ILHQ--A 
                        
 
Figure 5. Multiple sequence alignment. Amino acid sequence alignments for Aquifex aeolicus (AA), 
Clostridium difficile (CD), Escherichia coli (EC), Staphylococcus aureus (SA), Staphylococcus 
aureus (strain JH1, SA2), Salmonella typhi (ST), Salmonella typhimurium LT2 (ST2) DHQ1 
enzymes. Protein sequences were aligned using the CLUSTAL W (1.83) multiple sequence 
alignment (https://www.ebi.ac.uk/Tools/msa/clustalw2/). Fully conserved (*, grey) and functionally 
conserved (:, black) residues are highlighted.   
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Figure 6. Michaelis complex formation process obtained by MD simulations studies. The process 
involves: (a) substrate-covering loop folding triggered by the conserved Gln236 residue; (b) Loop 
flexibility reduction by formation of several hydrogen-bonding interactions within the loop residues; (c) 
Pushing the substrate into the Lys/His binding pocket by a combined action of the loop and Glu46 side 
chain. (d) Sealing of the active site with the entrance of Phe145 into the active site and its capture by 
interaction with the Met205 side chain. As a result of this process the Michaelis complex is obtained. 














Figure 9. Crystal structure of the St-DHQ1 covalently modified by epoxide 7. A) Unbiased 
electron density for the modified inhibitor 7 (pink) and its covalent attachment to Lys170 of St-
DHQ1 (light orange). A maximum-likelihood weighted 2Fo – Fc map contoured at 1σ is shown up to 
1.6 Å around the inhibitor molecule (light orange) and water molecule W285 (blue). B) Interactions 
of the modified inhibitor 7 with St-DHQ1. Hydrogen bonding and electrostatic interactions (blue) 





Figure 10. Proposed covalent modification mechanism of St-DHQ1 caused by irreversible 






Figure 11. Non-covalent inhibitors of DHQ1 from C. difficile discovered by high-throughput 
screening. 
 
 
 
 
 
